A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients With Ulcerative Colitis
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
SOR102-101 is a Phase 1, 3-part, randomised, double-blind, placebo-controlled, FIH study to
determine the safety, tolerability, and PK of single, ascending oral doses (SAD) of SOR102
(Part 1) and multiple oral doses (Part 2) of SOR102 in healthy adult participants, and to
assess the safety, tolerability, PK, and biological activity of multiple oral doses of SOR102
in patients with mild to severe UC (Part 3).